DDX60L Activators
Chemical activators of DDX60L are diverse molecules that engage the innate immune system's pattern recognition receptors (PRRs), inciting a cascade of signaling events that culminate in the activation of this protein, which plays a role in antiviral responses. Poly(I:C), a synthetic analog of double-stranded RNA, triggers the RIG-I-like receptor pathway, which is known to involve DDX60L in its suite of antiviral reactions. Similarly, 5'ppp-dsRNA, another viral mimic, engages these receptors to facilitate the activation of DDX60L. Poly(dA:dT), by mimicking double-stranded DNA, can initiate the cGAS-STING pathway, a cytosolic DNA sensing mechanism that likely incorporates the activation of DDX60L in its repertoire of immune responses.
Several agonists of Toll-like receptors also play a role in the activation of DDX60L. Resiquimod and Imiquimod, as agonists of TLR7 and TLR8, and Gardiquimod, targeting TLR7, are all capable of initiating signaling pathways that result in the activation of DDX60L. Loxoribine, another TLR7 agonist, also has the capability to activate DDX60L. Moreover, 2'3'-cGAMP, as an endogenous second messenger, activates the STING pathway, which has been associated with the induction of DDX60L activity. Lastly, CL097, a TLR7/8 agonists, triggers the MyD88-dependent signaling pathway that leads to the activation of NF-κB and IRF7, transcription factors involved in the regulation and activation of DDX60L.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Polyinosinic acid - polycytidylic acid sodium salt, double-stranded | 42424-50-0 | sc-204854 sc-204854A | 10 mg 100 mg | $139.00 $663.00 | 2 | |
As a synthetic analog of double-stranded RNA, Poly(I:C) activates the RIG-I-like receptor pathway, leading to the functional activation of DDX60L through its role in antiviral response mechanisms. | ||||||
R-848 | 144875-48-9 | sc-203231 sc-203231A sc-203231B sc-203231C | 5 mg 25 mg 100 mg 500 mg | $102.00 $306.00 $510.00 $1559.00 | 12 | |
Resiquimod, an agonist of Toll-like receptors 7 and 8, can stimulate the innate immune response, resulting in the activation of DDX60L as part of the downstream signaling pathway. | ||||||
Imiquimod | 99011-02-6 | sc-200385 sc-200385A | 100 mg 500 mg | $67.00 $284.00 | 6 | |
Imiquimod, similar to Resiquimod, functions as a Toll-like receptor 7 agonist, which can lead to the activation of DDX60L within the antiviral response signaling pathways. | ||||||
Gardiquimod | 1020412-43-4 | sc-221663 sc-221663A sc-221663B sc-221663C sc-221663D sc-221663E sc-221663F | 25 mg 50 mg 100 mg 250 mg 5 g 10 g 25 g | $157.00 $282.00 $516.00 $1177.00 $20138.00 $32779.00 $70753.00 | 1 | |
Gardiquimod, acting on Toll-like receptor 7, can initiate a cascade of immune responses that involve the activation of DDX60L as part of the cellular antiviral defense. | ||||||
Loxoribine | 121288-39-9 | sc-203118 sc-203118A | 25 mg 100 mg | $124.00 $390.00 | 1 | |
Loxoribine, as an agonist of Toll-like receptor 7, can stimulate the immune response, which in turn leads to the activation of DDX60L in the context of pathogen recognition. | ||||||
2′,3′-cGAMP | 1441190-66-4 | sc-507484 | 10 mg | $1800.00 | ||
2'3'-cyclic GMP-AMP is an endogenous second messenger that activates STING, leading to the activation of interferon regulatory factors and potentially the activation of DDX60L in the interferon signaling pathway. | ||||||
CL097 | 1026249-18-2 | sc-507394 | 5 mg | $135.00 | ||
CL097 is a TLR7/8 agonist that can activate the MyD88-dependent signaling pathway, leading to the activation of NF-κB and IRF7 which are transcription factors that can be involved in the activation of DDX60L in immune responses. | ||||||